Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer

被引：2

作者：

De Velasco, Marco A. ^{[1
]}

Kura, Yurie ^{[1
]}

Fujita, Kazutoshi ^{[2
]}

Uemura, Hirotsugu ^{[2
]}

机构：

[1] Kindai Univ, Fac Med, Dept Genome Biol, 377-2 Ohno Higashi, Osakasayama, Osaka 5898511, Japan

[2] Kindai Univ, Fac Med, Dept Urol, Osakasayama, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2024年 / 31卷 / 04期

基金：

日本学术振兴会;

关键词：

castration-resistant prostate cancer; immune checkpoint blockade; immune modulation; immune response; immunotherapy; tumor microenvironment; MHC CLASS-I; ANDROGEN RECEPTOR EXPRESSION; TUMOR-ASSOCIATED MACROPHAGES; PHASE-II; T-CELLS; MUTATIONAL LANDSCAPE; DOUBLE-BLIND; ANTI-PD-1; THERAPY; SEX-DIFFERENCES; PLUS DOCETAXEL;

D O I：

10.1111/iju.15378

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Human prostate cancer is a heterogenous malignancy that responds poorly to immunotherapy targeting immune checkpoints. The immunosuppressive tumor microenvironment that is typical of human prostate cancer has been the main obstacle to these treatments. The effectiveness of these therapies is also hindered by acquired resistance, leading to slow progress in prostate cancer immunotherapy. Results from the highly anticipated late-stage clinical trials of PD-1/PD-L1 immune checkpoint blockade in patients with advanced prostate cancer have highlighted some of the obstacles to immunotherapy. Despite the setbacks, there is much that has been learned about the mechanisms that drive resistance, and new strategies are being developed and tested. Here, we review the status of immune checkpoint blockade and the immunosuppressive tumor microenvironment and discuss factors contributing to innate and adaptive resistance to immune checkpoint blockade within the context of prostate cancer. We then examine current strategies aiming to overcome these challenges as well as prospects.

引用

页码：307 / 324

页数：18

共 213 条

[1] Genomic correlates of clinical outcome in advanced prostate cancer [J].

Abida, Wassim ;

Cyrta, Joanna ;

Heller, Glenn ;

Prandi, Davide ;

Armenia, Joshua ;

Coleman, Ilsa ;

Cieslik, Marcin ;

Benelli, Matteo ;

Robinson, Dan ;

Van Allen, Eliezer M. ;

Sboner, Andrea ;

Fedrizzi, Tarcisio ;

Mosquera, Juan Miguel ;

Robinson, Brian D. ;

De Sarkar, Navonil ;

Kunju, Lakshmi P. ;

Tomlins, Scott ;

Wu, Yi Mi ;

Rodrigues, Daniel Nava ;

Loda, Massimo ;

Gopalan, Anuradha ;

Reuter, Victor E. ;

Pritchard, Colin C. ;

Mateo, Joaquin ;

Bianchini, Diletta ;

Miranda, Susana ;

Carreira, Suzanne ;

Rescigno, Pasquale ;

Filipenko, Julie ;

Vinson, Jacob ;

Montgomery, Robert B. ;

Beltran, Himisha ;

Heath, Elisabeth I. ;

Scher, Howard I. ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen ;

Schultz, Nikolaus ;

deBono, Johann S. ;

Demichelis, Francesca ;

Nelson, Peter S. ;

Rubin, Mark A. ;

Chinnaiyan, Arul M. ;

Sawyers, Charles L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) :11428-11436

[2] Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade [J].

Abida, Wassim ;

Cheng, Michael L. ;

Armenia, Joshua ;

Middha, Sumit ;

Autio, Karen A. ;

Vargas, Hebert Alberto ;

Rathkopf, Dana ;

Morris, Michael J. ;

Danila, Daniel C. ;

Slovin, Susan F. ;

Carbone, Emily ;

Barnett, Ethan S. ;

Hullings, Melanie ;

Hechtman, Jaclyn F. ;

Zehir, Ahmet ;

Shia, Jinru ;

Jonsson, Philip ;

Stadler, Zsofia K. ;

Srinivasan, Preethi ;

Laudone, Vincent P. ;

Reuter, Victor ;

Wolchok, Jedd D. ;

Socci, Nicholas D. ;

Taylor, Barry S. ;

Berger, Michael F. ;

Kantoff, Philip W. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Solit, David B. ;

Gopalan, Anuradha ;

Scher, Howard I. .

JAMA ONCOLOGY, 2019, 5 (04) :471-478

[3] Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) [J].

Agarwal, Neeraj ;

McGregor, Bradley ;

Maughan, Benjamin L. ;

Dorff, Tanya B. ;

Kelly, William ;

Fang, Bruno ;

McKay, Rana R. ;

Singh, Parminder ;

Pagliaro, Lance ;

Dreicer, Robert ;

Srinivas, Sandy ;

Loriot, Yohann ;

Vaishampayan, Ulka ;

Goel, Sanjay ;

Curran, Dominic ;

Panneerselvam, Ashok ;

Schwickart, Martin ;

Choueiri, Toni K. ;

Pal, Sumanta .

LANCET ONCOLOGY, 2022, 23 (07) :899-909

[4] AMADEUS TRIAL: TUMOR AGNOSTIC PRE- AND ONTREATMENT BIOMARKERS OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB CORRELATE WITH ONTREATMENT TUMORAL T CELL INFILTRATION [J].

Alayli, Farah ;

Okrah, Kwame ;

Tsimberidou, Apostolia ;

Drakaki, Alexandra ;

Khalil, Danny ;

Khan, Saad ;

Hodi, Stephen ;

Oh, David ;

Amouzgar, Meelad ;

Guatam, Shikha ;

Kageyama, Robin ;

Pfeiffer, Shannon ;

Meier, Stefanie ;

Cabanski, Christopher ;

Da Silva, Diane ;

Kumar, Dinesh ;

Santulli-Marotto, Sandra ;

Tetzlaff, Michael ;

Foo, Wai Chin ;

Hollman, Travis ;

Li, Yanyun ;

Adamow, Mathew ;

Wong, Philip ;

Spasic, Marko ;

Chen, Richard ;

Bucktrout, Samantha ;

Fairchild, Justin ;

Butterfield, Lisa ;

LaVallee, Theresa ;

Padron, Lacey ;

Salvador, Lisa ;

O'Donnell-Tormey, Jill ;

Dugan, Ute ;

Sharma, Padmanee .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 :A614-A614

[5] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[6]

Antonarakis ES, 2023, J CLIN ONCOL, V41, P3839, DOI 10.1200/JCO.23.00233

[7] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].

Antonarakis, Emmanuel S. ;

Piulats, Josep M. ;

Gross-Goupil, Marine ;

Goh, Jeffrey ;

Ojamaa, Kristiina ;

Hoimes, Christopher J. ;

Vaishampayan, Ulka ;

Berger, Ranaan ;

Sezer, Ahmet ;

Alanko, Tuomo ;

de Wit, Ronald ;

Li, Chunde ;

Omlin, Aurelius ;

Procopio, Giuseppe ;

Fukasawa, Satoshi ;

Tabata, Ken-ichi ;

Park, Se Hoon ;

Feyerabend, Susan ;

Drake, Charles G. ;

Wu, Haiyan ;

Qiu, Ping ;

Kim, Jeri ;

Poehlein, Christian ;

de Bono, Johann Sebastian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[8]

Attard G., 2023, Janssen Pharmaceutical Companies of Johnson & Johnson

[9]

Augello MA, 2019, CANCER CELL, V35, P603, DOI [10.1016/j.ccell.2019.04.012, 10.1016/j.ccell.2019.03.001]

[10] Chronic inflammation and the hallmarks of aging [J].

Baechle, Jordan J. ;

Chen, Nan ;

Makhijani, Priya ;

Winer, Shawn ;

Furman, David ;

Winer, Daniel A. .

MOLECULAR METABOLISM, 2023, 74

← 1 2 3 4 5 6 7 8 9 10 →